QUEENSBURY, N.Y., Dec 19, 2007 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, today commented on the clinical studies on which the FDA based its December 11, 2007 Public Health Notification regarding the deaths associated with the use of radio frequency ablation of lung tumors. No AngioDynamics' RITA radio frequency ablation (RF) probes were used in these studies.

AngioDynamics has conducted a 106 patient clinical trial, RAPTURE, involving the use of its RF technology to treat lung malignancies. The trial included patients from Europe, Australia and the United States. There were no deaths within 30 days of treatment. Further, the Company knows of no reported deaths in published studies in which AngioDynamics RF probes were used to treat a variety of lung tumors. The Company expects the RAPTURE clinical trial results to be published in the first half of 2008.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 x1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Julie Huang, 415-652-9100 (Investor Relations)
jhuang@evcgroup.com
Doug Sherk, 415-652-9100 (Investor Relations)


dsherk@evcgroup.com
Steve DiMattia, 917-620-0590 (Media)
sdimattia@evcgroup.com